179 related articles for article (PubMed ID: 19222478)
21. Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.
Cascavilla N; De Stefano V; Pane F; Pancrazzi A; Iurlo A; Gobbi M; Palandri F; Specchia G; Liberati AM; D'Adda M; Gaidano G; Fjerza R; Achenbach H; Smith J; Wilde P; Vannucchi AM
Drug Des Devel Ther; 2015; 9():2687-94. PubMed ID: 26028965
[TBL] [Abstract][Full Text] [Related]
22. Causal role for JAK2 V617F in thrombosis.
Fleischman AG; Tyner JW
Blood; 2013 Nov; 122(23):3705-6. PubMed ID: 24288407
[TBL] [Abstract][Full Text] [Related]
23. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain.
Ziakas PD
Haematologica; 2008 Sep; 93(9):1412-4. PubMed ID: 18641024
[No Abstract] [Full Text] [Related]
24. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules.
Falanga A; Marchetti M; Vignoli A; Balducci D; Russo L; Guerini V; Barbui T
Exp Hematol; 2007 May; 35(5):702-11. PubMed ID: 17577920
[TBL] [Abstract][Full Text] [Related]
25. In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm.
Lambert JR; Everington T; Linch DC; Gale RE
Blood; 2009 Oct; 114(14):3018-23. PubMed ID: 19541820
[TBL] [Abstract][Full Text] [Related]
26. Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry.
Melillo L; Tieghi A; Candoni A; Radaelli F; Ciancia R; Specchia G; Martino B; Scalzulli PR; Latagliata R; Palmieri F; Usala E; Valente D; Valvano MR; Cedrone M; Comitini G; Martinelli V; Cascavilla N; Gugliotta L
Am J Hematol; 2009 Oct; 84(10):636-40. PubMed ID: 19705431
[TBL] [Abstract][Full Text] [Related]
27. Comparison of coated-platelet levels in patients with essential thrombocythemia with and without hydroxyurea treatment.
Reményi G; Szász R; Debreceni IB; Szarvas M; Batár P; Nagy B; Kappelmayer J; Udvardy M
Platelets; 2013; 24(6):486-92. PubMed ID: 23216455
[TBL] [Abstract][Full Text] [Related]
28. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.
Duek A; Lundberg P; Shimizu T; Grisouard J; Karow A; Kubovcakova L; Hao-Shen H; Dirnhofer S; Skoda RC
Blood; 2014 Jun; 123(25):3943-50. PubMed ID: 24820309
[TBL] [Abstract][Full Text] [Related]
29. Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation.
Er TK; Lin SF; Chang JG; Hsieh LL; Lin SK; Wang LH; Lin CW; Chang CS; Liu TC
Clin Chim Acta; 2009 Oct; 408(1-2):39-44. PubMed ID: 19595684
[TBL] [Abstract][Full Text] [Related]
30. CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients.
Trifa AP; Popp RA; Cucuianu A; Bănescu C; Tevet M; Martin B; Murat M; Vesa SC; Dima D; Cândea M; Militaru MS; Pop IV
Br J Haematol; 2015 Jan; 168(1):151-3. PubMed ID: 25103987
[No Abstract] [Full Text] [Related]
31. Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status.
Treliński J; Wierzbowska A; Krawczyńska A; Sakowicz A; Pietrucha T; Smolewski P; Robak T; Chojnowski K
Leuk Lymphoma; 2010 Sep; 51(9):1727-33. PubMed ID: 20615083
[TBL] [Abstract][Full Text] [Related]
32. Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations during the follow-up: causal or casual association?
Ciresi A; Guarnotta V; Tomasello L; Calò V; Russo A; Galluzzo A; Giordano C
Growth Horm IGF Res; 2012 Apr; 22(2):92-6. PubMed ID: 22364960
[TBL] [Abstract][Full Text] [Related]
33. Reemergence of JAK2 V617F clone heralds extramedullary leukemia relapse after BMT for transformed essential thrombocytosis.
Au WY; Fung A; Lie AK; Lam KY; Lam CC; Kwong YL
Ann Hematol; 2007 Feb; 86(2):145-7. PubMed ID: 17111143
[No Abstract] [Full Text] [Related]
34. Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients.
Kouroupi E; Zoi K; Parquet N; Zoi C; Kiladjian JJ; Grigoraki V; Vainchenker W; Lellouche F; Marzac C; Schlageter MH; Dosquet C; Scott LM; Fenaux P; Loukopoulos D; Chomienne C; Cassinat B
Br J Haematol; 2008 Aug; 142(4):676-9. PubMed ID: 18503583
[No Abstract] [Full Text] [Related]
35. Activation loop tyrosines allow the JAK2(V617F) mutant to attain hyperactivation.
Kundrapu K; Colenberg L; Duhé RJ
Cell Biochem Biophys; 2008; 52(2):103-12. PubMed ID: 18841497
[TBL] [Abstract][Full Text] [Related]
36. JAK2 V617F positive essential thrombocythemia developing in a patient with CD5⁻ chronic lymphocytic leukemia.
Wei J; Wang C; Qin YW; Zhu J; Gao YR; Cai Q; Yan SK
Chin Med J (Engl); 2012 Jun; 125(11):2076-9. PubMed ID: 22884083
[TBL] [Abstract][Full Text] [Related]
37. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
[TBL] [Abstract][Full Text] [Related]
38. Disappearance of JAK2 V617F mutation in a rapid leukemic transformed essential thrombocythemia patient.
Hsiao HH; Yang WC; Liu YC; Lee CP; Lin SF
Leuk Res; 2008 Aug; 32(8):1323-4. PubMed ID: 18078991
[No Abstract] [Full Text] [Related]
39. JAK2 V617F mutation analysis in different myeloid lineages (granulocytes, platelets, CFU-MK, BFU-E and CFU-GM) in essential thrombocythemia patients.
Florensa L; Bellosillo B; Besses C; Puigdecanet E; Espinet B; Pérez-Vila E; Longarón R; Vilà RM; Solé F; Serrano S
Leukemia; 2006 Oct; 20(10):1903-5. PubMed ID: 16888614
[No Abstract] [Full Text] [Related]
40. Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation.
Mercier F; Monczak Y; François M; Prchal J; Galipeau J
Exp Hematol; 2009 Mar; 37(3):416-20. PubMed ID: 19135773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
